Tempus AI, Inc. TEM

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

2facts worth reading about the other 9 checks found nothing to note

• report_problem
  Receivables growing faster than revenue

  Receivables +101.0% ($154.8M to $311.2M) vs revenue +83.4% ($693.4M to $1.3B), +17.6 pts apart
• report_problem
  Critical audit matters changed

  New this year: Diagnostics Revenue - Variable Consideration for Clinical Orders (“As described in Note 2 to the consolidated financial statements, the Company recognized Diagnostics revenue of $955.4 million for the year ended December 31, 2025, of which $884.5 million relates to clinical orders. The Company generally recognizes revenue for its Diagnostics product offering when i”); Acquisition of Ambry - Valuation of Customer Relationships and Developed Technology - Biotech (“As described in Note 3 to the consolidated financial statements, on February 3, 2025, the Company completed its acquisition of Ambry for total consideration of $692.3 million. Of the acquired intangibles, $234.0 million of customer relationships and $114.0 million of developed technology - biotech w”)
• check_circle
  Cash from operations −$218.1M vs net income −$245.0M (FY ending Dec 31, 2025)

1. add_circleItem 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1Anorth_east

   Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests. Genetic testing has raised ethical, legal and social issues regarding privacy rights and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the…

2. add_circleItem 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1Anorth_east

   In April 2025, we entered into expanded multi-year strategic collaborations with AstraZeneca and Pathos for the development of a foundation model in the field of oncology. Under this collaboration, we will work together with AstraZeneca and Pathos to build the foundation model, which will incorporate our multi-modal de-identified…

3. add_circleItem 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1Anorth_east

   Since its enactment, there have been efforts to repeal, replace, and amend all or part of the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, which is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed…

4. add_circleItem 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1Anorth_east

   The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at the Department of Health and Human Services, the FDA, CMS and related agencies. Such actions and policies may, among other things, significantly reduce U.S. medical device prices, potentially impacting…

• TEM32
• PCOR22
• RBRK20
• GWRE15
• KVYO12
• ALAB8

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.